Does the media prefer LRMR or SNDX?

In the previous week, Syndax Pharmaceuticals had 1 more articles in the media than Larimar Therapeutics. MarketBeat recorded 4 mentions for Syndax Pharmaceuticals and 3 mentions for Larimar Therapeutics. Syndax Pharmaceuticals' average media sentiment score of 0.88 beat Larimar Therapeutics' score of 0.65 indicating that Syndax Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Larimar Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Syndax Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is LRMR or INBX more profitable?

Larimar Therapeutics' return on equity of -137.39% beat Inhibrx Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Larimar Therapeutics N/A -137.39% -97.65% Inhibrx Biosciences N/A -563.90% -83.48%

Does the media favor LRMR or INBX?

In the previous week, Inhibrx Biosciences had 6 more articles in the media than Larimar Therapeutics. MarketBeat recorded 9 mentions for Inhibrx Biosciences and 3 mentions for Larimar Therapeutics. Inhibrx Biosciences' average media sentiment score of 1.05 beat Larimar Therapeutics' score of 0.65 indicating that Inhibrx Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Larimar Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Inhibrx Biosciences 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ALVO or LRMR?

In the previous week, Alvotech had 4 more articles in the media than Larimar Therapeutics. MarketBeat recorded 7 mentions for Alvotech and 3 mentions for Larimar Therapeutics. Larimar Therapeutics' average media sentiment score of 0.65 beat Alvotech's score of 0.44 indicating that Larimar Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alvotech 3 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Larimar Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor NVAX or LRMR?

In the previous week, Novavax had 8 more articles in the media than Larimar Therapeutics. MarketBeat recorded 11 mentions for Novavax and 3 mentions for Larimar Therapeutics. Novavax's average media sentiment score of 0.66 beat Larimar Therapeutics' score of 0.65 indicating that Novavax is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novavax 6 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive Larimar Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Larimar Therapeutics (LRMR) Competitors

$3.79 -0.01 (-0.26%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$3.92 +0.13 (+3.40%)

As of 09/18/2026 07:32 PM Eastern

Compare

LRMR vs. SNDX, INBX, ALVO, ANAB, and NVAX

Should you buy Larimar Therapeutics stock or one of its competitors? Larimar Therapeutics's main competitors and comparable companies include Syndax Pharmaceuticals (SNDX), Inhibrx Biosciences (INBX), Alvotech (ALVO), AnaptysBio (ANAB), and Novavax (NVAX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Larimar Therapeutics compare to Syndax Pharmaceuticals?

Larimar Therapeutics (NASDAQ:LRMR) and Syndax Pharmaceuticals (NASDAQ:SNDX) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, valuation, risk, institutional ownership, dividends, profitability, media sentiment and analyst recommendations.

In the previous week, Syndax Pharmaceuticals had 1 more articles in the media than Larimar Therapeutics. MarketBeat recorded 4 mentions for Syndax Pharmaceuticals and 3 mentions for Larimar Therapeutics. Syndax Pharmaceuticals' average media sentiment score of 0.88 beat Larimar Therapeutics' score of 0.65 indicating that Syndax Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Larimar Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Syndax Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Larimar Therapeutics has higher earnings, but lower revenue than Syndax Pharmaceuticals. Syndax Pharmaceuticals is trading at a lower price-to-earnings ratio than Larimar Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Larimar Therapeutics	N/A	N/A	-$165.67M	-$1.95	N/A
Syndax Pharmaceuticals	$172.35M	9.06	-$285.42M	-$2.51	N/A

91.9% of Larimar Therapeutics shares are owned by institutional investors. 4.0% of Larimar Therapeutics shares are owned by company insiders. Comparatively, 4.8% of Syndax Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Larimar Therapeutics presently has a consensus price target of $11.86, suggesting a potential upside of 212.85%. Syndax Pharmaceuticals has a consensus price target of $42.30, suggesting a potential upside of 140.07%. Given Larimar Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Larimar Therapeutics is more favorable than Syndax Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Larimar Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	3.00
Syndax Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82

Larimar Therapeutics has a beta of 0.74, suggesting that its share price is 26% less volatile than the broader market. Comparatively, Syndax Pharmaceuticals has a beta of 0.37, suggesting that its share price is 63% less volatile than the broader market.

Larimar Therapeutics has a net margin of 0.00% compared to Syndax Pharmaceuticals' net margin of -87.52%. Larimar Therapeutics' return on equity of -137.39% beat Syndax Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Larimar Therapeutics	N/A	-137.39%	-97.65%
Syndax Pharmaceuticals	-87.52%	-372.94%	-39.11%

Summary

Larimar Therapeutics beats Syndax Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does Larimar Therapeutics compare to Inhibrx Biosciences?

Larimar Therapeutics (NASDAQ:LRMR) and Inhibrx Biosciences (NASDAQ:INBX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, profitability, media sentiment, institutional ownership and valuation.

Larimar Therapeutics' return on equity of -137.39% beat Inhibrx Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Larimar Therapeutics	N/A	-137.39%	-97.65%
Inhibrx Biosciences	N/A	-563.90%	-83.48%

Inhibrx Biosciences has higher revenue and earnings than Larimar Therapeutics. Inhibrx Biosciences is trading at a lower price-to-earnings ratio than Larimar Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Larimar Therapeutics	N/A	N/A	-$165.67M	-$1.95	N/A
Inhibrx Biosciences	$1.30M	1,238.18	-$140.05M	-$8.88	N/A

91.9% of Larimar Therapeutics shares are owned by institutional investors. Comparatively, 82.5% of Inhibrx Biosciences shares are owned by institutional investors. 4.0% of Larimar Therapeutics shares are owned by company insiders. Comparatively, 18.3% of Inhibrx Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Inhibrx Biosciences had 6 more articles in the media than Larimar Therapeutics. MarketBeat recorded 9 mentions for Inhibrx Biosciences and 3 mentions for Larimar Therapeutics. Inhibrx Biosciences' average media sentiment score of 1.05 beat Larimar Therapeutics' score of 0.65 indicating that Inhibrx Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Larimar Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Inhibrx Biosciences	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Larimar Therapeutics presently has a consensus price target of $11.86, indicating a potential upside of 212.85%. Inhibrx Biosciences has a consensus price target of $197.50, indicating a potential upside of 80.61%. Given Larimar Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Larimar Therapeutics is more favorable than Inhibrx Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Larimar Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	3.00
Inhibrx Biosciences	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.50

Larimar Therapeutics has a beta of 0.74, suggesting that its stock price is 26% less volatile than the broader market. Comparatively, Inhibrx Biosciences has a beta of 3.66, suggesting that its stock price is 266% more volatile than the broader market.

Summary

Larimar Therapeutics beats Inhibrx Biosciences on 8 of the 15 factors compared between the two stocks.

How does Larimar Therapeutics compare to Alvotech?

Alvotech (NASDAQ:ALVO) and Larimar Therapeutics (NASDAQ:LRMR) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, risk, profitability, institutional ownership and media sentiment.

In the previous week, Alvotech had 4 more articles in the media than Larimar Therapeutics. MarketBeat recorded 7 mentions for Alvotech and 3 mentions for Larimar Therapeutics. Larimar Therapeutics' average media sentiment score of 0.65 beat Alvotech's score of 0.44 indicating that Larimar Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alvotech	3 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Larimar Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Alvotech currently has a consensus target price of $8.50, indicating a potential upside of 44.80%. Larimar Therapeutics has a consensus target price of $11.86, indicating a potential upside of 212.85%. Given Larimar Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Larimar Therapeutics is more favorable than Alvotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alvotech	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
Larimar Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	3.00

Alvotech has higher revenue and earnings than Larimar Therapeutics. Alvotech is trading at a lower price-to-earnings ratio than Larimar Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alvotech	$588.90M	3.01	$27.92M	-$0.61	N/A
Larimar Therapeutics	N/A	N/A	-$165.67M	-$1.95	N/A

91.9% of Larimar Therapeutics shares are owned by institutional investors. 0.5% of Alvotech shares are owned by insiders. Comparatively, 4.0% of Larimar Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Alvotech has a beta of 0.22, meaning that its stock price is 78% less volatile than the broader market. Comparatively, Larimar Therapeutics has a beta of 0.74, meaning that its stock price is 26% less volatile than the broader market.

Larimar Therapeutics has a net margin of 0.00% compared to Alvotech's net margin of -36.31%. Alvotech's return on equity of -11.92% beat Larimar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alvotech	-36.31%	-11.92%	-11.73%
Larimar Therapeutics	N/A	-137.39%	-97.65%

Summary

Larimar Therapeutics beats Alvotech on 10 of the 16 factors compared between the two stocks.

How does Larimar Therapeutics compare to AnaptysBio?

AnaptysBio (NASDAQ:ANAB) and Larimar Therapeutics (NASDAQ:LRMR) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, risk, earnings, valuation, analyst recommendations, media sentiment, dividends and institutional ownership.

In the previous week, Larimar Therapeutics had 3 more articles in the media than AnaptysBio. MarketBeat recorded 3 mentions for Larimar Therapeutics and 0 mentions for AnaptysBio. Larimar Therapeutics' average media sentiment score of 0.65 beat AnaptysBio's score of 0.00 indicating that Larimar Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
AnaptysBio	Neutral
Larimar Therapeutics	Positive

AnaptysBio has a beta of 0.71, suggesting that its share price is 29% less volatile than the broader market. Comparatively, Larimar Therapeutics has a beta of 0.74, suggesting that its share price is 26% less volatile than the broader market.

91.9% of Larimar Therapeutics shares are owned by institutional investors. 31.5% of AnaptysBio shares are owned by company insiders. Comparatively, 4.0% of Larimar Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

AnaptysBio presently has a consensus target price of $79.85, indicating a potential upside of 44.65%. Larimar Therapeutics has a consensus target price of $11.86, indicating a potential upside of 212.85%. Given Larimar Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Larimar Therapeutics is more favorable than AnaptysBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AnaptysBio	1 Sell rating(s)	3 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.67
Larimar Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	3.00

Larimar Therapeutics has a net margin of 0.00% compared to AnaptysBio's net margin of -11.53%. AnaptysBio's return on equity of 0.00% beat Larimar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AnaptysBio	-11.53%	N/A	-7.75%
Larimar Therapeutics	N/A	-137.39%	-97.65%

AnaptysBio has higher revenue and earnings than Larimar Therapeutics. AnaptysBio is trading at a lower price-to-earnings ratio than Larimar Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AnaptysBio	$234.60M	6.97	-$13.23M	-$1.08	N/A
Larimar Therapeutics	N/A	N/A	-$165.67M	-$1.95	N/A

Summary

Larimar Therapeutics beats AnaptysBio on 9 of the 16 factors compared between the two stocks.

How does Larimar Therapeutics compare to Novavax?

Novavax (NASDAQ:NVAX) and Larimar Therapeutics (NASDAQ:LRMR) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, earnings, valuation, risk, profitability and dividends.

In the previous week, Novavax had 8 more articles in the media than Larimar Therapeutics. MarketBeat recorded 11 mentions for Novavax and 3 mentions for Larimar Therapeutics. Novavax's average media sentiment score of 0.66 beat Larimar Therapeutics' score of 0.65 indicating that Novavax is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novavax	6 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
Larimar Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

53.0% of Novavax shares are held by institutional investors. Comparatively, 91.9% of Larimar Therapeutics shares are held by institutional investors. 1.6% of Novavax shares are held by company insiders. Comparatively, 4.0% of Larimar Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Larimar Therapeutics has a net margin of 0.00% compared to Novavax's net margin of -59.87%. Novavax's return on equity of -14.82% beat Larimar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novavax	-59.87%	-14.82%	-13.35%
Larimar Therapeutics	N/A	-137.39%	-97.65%

Novavax has a beta of 2.45, indicating that its stock price is 145% more volatile than the broader market. Comparatively, Larimar Therapeutics has a beta of 0.74, indicating that its stock price is 26% less volatile than the broader market.

Novavax currently has a consensus price target of $14.00, suggesting a potential upside of 38.48%. Larimar Therapeutics has a consensus price target of $11.86, suggesting a potential upside of 212.85%. Given Larimar Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Larimar Therapeutics is more favorable than Novavax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novavax	2 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.33
Larimar Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	3.00

Novavax has higher revenue and earnings than Larimar Therapeutics. Novavax is trading at a lower price-to-earnings ratio than Larimar Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novavax	$1.12B	1.48	$440.30M	-$1.52	N/A
Larimar Therapeutics	N/A	N/A	-$165.67M	-$1.95	N/A

Summary

Novavax and Larimar Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

Get Larimar Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LRMR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LRMR vs. The Competition

Export

Metric	Larimar Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$394.76M	$3.92B	$7.24B	$13.14B
Dividend Yield	N/A	3.65%	2.57%	12.30%
P/E Ratio	-1.94	14.30	275.79	25.40
Price / Sales	N/A	1,415.50	695.58	114.44
Price / Cash	N/A	110.75	77.42	51.66
Price / Book	4.03	15.45	10.46	6.33
Net Income	-$165.67M	-$22.86M	$3.49B	$358.33M
7 Day Performance	-3.32%	-1.21%	0.59%	1.12%
1 Month Performance	-10.82%	-4.42%	-2.01%	-2.67%
1 Year Performance	-9.76%	37.81%	18.09%	6.01%

Larimar Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LRMR Larimar Therapeutics	3.3827 of 5 stars	$3.79 -0.3%	$11.86 +212.9%	-11.4%	$394.76M	N/A	N/A	71
SNDX Syndax Pharmaceuticals	3.4575 of 5 stars	$18.35 +0.9%	$42.30 +130.5%	+14.0%	$1.61B	$172.35M	N/A	298	Analyst Downgrade
INBX Inhibrx Biosciences	3.768 of 5 stars	$110.47 +1.1%	$197.50 +78.8%	+310.3%	$1.61B	N/A	N/A	110	Positive News Analyst Forecast Insider Trade
ALVO Alvotech	3.1915 of 5 stars	$5.05 -4.5%	$7.50 +48.5%	-24.9%	$1.60B	$588.90M	N/A	1,460	Analyst Upgrade
ANAB AnaptysBio	2.0692 of 5 stars	$54.11 +0.4%	$79.85 +47.6%	+161.9%	$1.60B	$234.60M	N/A	104	Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LRMR) was last updated on 9/19/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Larimar Therapeutics (LRMR) Competitors

LRMR vs. SNDX, INBX, ALVO, ANAB, and NVAX

How does Larimar Therapeutics compare to Syndax Pharmaceuticals?

Summary

How does Larimar Therapeutics compare to Inhibrx Biosciences?

Summary

How does Larimar Therapeutics compare to Alvotech?

Summary

How does Larimar Therapeutics compare to AnaptysBio?

Summary

How does Larimar Therapeutics compare to Novavax?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LRMR vs. The Competition

Larimar Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Larimar Therapeutics (LRMR) Competitors

LRMR vs. SNDX, INBX, ALVO, ANAB, and NVAX

How does Larimar Therapeutics compare to Syndax Pharmaceuticals?

Does the media prefer LRMR or SNDX?

Which has better valuation & earnings, LRMR or SNDX?

Do insiders & institutionals have more ownership in LRMR or SNDX?

Do analysts recommend LRMR or SNDX?

Which has more volatility & risk, LRMR or SNDX?

Is LRMR or SNDX more profitable?

Summary

How does Larimar Therapeutics compare to Inhibrx Biosciences?

Is LRMR or INBX more profitable?

Which has stronger earnings & valuation, LRMR or INBX?

Do insiders & institutionals believe in LRMR or INBX?

Does the media favor LRMR or INBX?

Do analysts rate LRMR or INBX?

Which has more risk and volatility, LRMR or INBX?

Summary

How does Larimar Therapeutics compare to Alvotech?

Does the media favor ALVO or LRMR?

Do analysts prefer ALVO or LRMR?

Which has preferable valuation & earnings, ALVO or LRMR?

Do institutionals and insiders hold more shares of ALVO or LRMR?

Which has more risk & volatility, ALVO or LRMR?

Is ALVO or LRMR more profitable?

Summary

How does Larimar Therapeutics compare to AnaptysBio?

Does the media refer more to ANAB or LRMR?

Which has more risk and volatility, ANAB or LRMR?

Do institutionals & insiders believe in ANAB or LRMR?

Do analysts rate ANAB or LRMR?

Is ANAB or LRMR more profitable?

Which has higher earnings & valuation, ANAB or LRMR?

Summary

How does Larimar Therapeutics compare to Novavax?

Does the media favor NVAX or LRMR?

Do institutionals & insiders believe in NVAX or LRMR?

Is NVAX or LRMR more profitable?

Which has more volatility & risk, NVAX or LRMR?

Do analysts rate NVAX or LRMR?

Which has higher earnings and valuation, NVAX or LRMR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LRMR vs. The Competition

Larimar Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools